Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.55 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | LATS1 | O95835 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16235941 | 0.98 | ROCK2 (0.53) | ROCK2ROCK1CDC42BPBADRB2NCF1 | |
| SCHEMBL3345307 | 0.89 | ROCK2 (0.59) | ROCK2ROCK1CDC42BPBADRB2NCF1 | |
| SCHEMBL19095141 | 0.81 | ROCK2 (0.53) | ROCK2ROCK1CDC42BPBALDH1A1GRM1 | |
| SCHEMBL233169 | 0.78 | ADRB1 (0.58) | ROCK2ROCK1CDC42BPBNCF1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20139829 | 0.76 | ADRB1 (0.56) | ROCK2ROCK1CDC42BPBNCF1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29882725 | 0.76 | ADRB1 (0.56) | ROCK2ROCK1CDC42BPBNCF1ALDH1A1 | |
| SCHEMBL16236035 | 0.76 | GRM1 (0.50) | GRM1DRD2 | |
| SCHEMBL23124420 | 0.75 | ADRB1 (0.58) | ADRB2NCF1PLD1LATS1CHRNB2 | |
| SCHEMBL2326783 | 0.74 | GRM1 (0.46) | ROCK2ROCK1CDC42BPBALDH1A1GRM1 | |
| Hydrochloric Acid SCHEMBL25249300 | 0.73 | ADRB1 (0.58) | ADRB2NCF1PLD1ALDH1A1LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014184248-A2 | TRPA1 ANTAGONIST COMPOUNDS | Acturum Life Science AB (SE) | 2014-11-20 | — | — | WO | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| EP-2134687-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | AstraZeneca AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | ROCK2 2969/4885ROCK1 2888/4885CDC42BPB 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.